BACTI_B: Profitability maintained despite lower revenues, with strategic partnerships driving future growth

About this update from Bactiguard Holding Ab

Q1 2026 delivered continued EBITDA profitability despite a 16% revenue decline, mainly due to lower BD shipments and timing effects. Strategic partnerships advanced, with BD launching coated Foley catheters in Europe and Zimmer Biomet transitioning to a new business setup. Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Bactiguard Holding Ab